Avanti Desai1, Mi-Yeon Jung2, Ana Olivera2, Alasdair M Gilfillan2, Calman Prussin2, Arnold S Kirshenbaum2, Michael A Beaven3, Dean D Metcalfe2. 1. Laboratory of Allergic Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Md. Electronic address: avanti.desai@nih.gov. 2. Laboratory of Allergic Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Md. 3. Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md.
Abstract
BACKGROUND: IL-6, levels of which are reported to be increased in association with mastocytosis, asthma, and urticaria, is used in conjunction with stem cell factor to generate CD34(+) cell-derived primary human mast cell (HuMC) cultures. Despite these associations, the effects on and mechanisms by which prolonged exposure to IL-6 alters HuMC numbers and function are not well understood. OBJECTIVES: We sought to study the effect of IL-6 on HuMC function, the mechanisms by which IL-6 exerts its effects, and the relationship of these findings to mastocytosis. METHODS: HuMCs were cultured in stem cell factor with or without IL-6. Responses to FcεRI aggregation and expression of proteases and receptors, including the soluble IL-6 receptor (sIL-6R), were then quantitated. Epigenetic changes in suppressor of cytokine signaling 3 (SOCS3) were determined by using methylation-specific PCR. Serum samples from healthy control subjects and patients with mastocytosis were assayed for IL-6, tryptase, and sIL-6R. RESULTS: IL-6 enhanced mast cell (MC) proliferation, maturation, and reactivity after FcεRI aggregation. IL-6 reduced expression of SOCS3, which correlated with methylation of the SOCS3 promoter and increased expression and activation of signal transducer and activator of transcription 3. IL-6 also suppressed constitutive production of sIL-6R, and serum levels of sIL-6R were similarly reduced in patients with mastocytosis. CONCLUSION: IL-6 increases MC proliferation and formation of a more reactive phenotype enabled by suppressing proteolytic cleavage of sIL-6R from IL-6R and downregulation of the SOCS3 autoinhibitory pathway. We suggest IL-6 blockade might ameliorate MC-related symptoms and pathology in patients with MC-related diseases associated with increased IL-6 levels, including mastocytosis. Published by Elsevier Inc.
BACKGROUND:IL-6, levels of which are reported to be increased in association with mastocytosis, asthma, and urticaria, is used in conjunction with stem cell factor to generate CD34(+) cell-derived primary human mast cell (HuMC) cultures. Despite these associations, the effects on and mechanisms by which prolonged exposure to IL-6 alters HuMC numbers and function are not well understood. OBJECTIVES: We sought to study the effect of IL-6 on HuMC function, the mechanisms by which IL-6 exerts its effects, and the relationship of these findings to mastocytosis. METHODS: HuMCs were cultured in stem cell factor with or without IL-6. Responses to FcεRI aggregation and expression of proteases and receptors, including the soluble IL-6 receptor (sIL-6R), were then quantitated. Epigenetic changes in suppressor of cytokine signaling 3 (SOCS3) were determined by using methylation-specific PCR. Serum samples from healthy control subjects and patients with mastocytosis were assayed for IL-6, tryptase, and sIL-6R. RESULTS:IL-6 enhanced mast cell (MC) proliferation, maturation, and reactivity after FcεRI aggregation. IL-6 reduced expression of SOCS3, which correlated with methylation of the SOCS3 promoter and increased expression and activation of signal transducer and activator of transcription 3. IL-6 also suppressed constitutive production of sIL-6R, and serum levels of sIL-6R were similarly reduced in patients with mastocytosis. CONCLUSION:IL-6 increases MC proliferation and formation of a more reactive phenotype enabled by suppressing proteolytic cleavage of sIL-6R from IL-6R and downregulation of the SOCS3 autoinhibitory pathway. We suggest IL-6 blockade might ameliorate MC-related symptoms and pathology in patients with MC-related diseases associated with increased IL-6 levels, including mastocytosis. Published by Elsevier Inc.
Entities:
Keywords:
IL-6; Mast cells; mastocytosis; signal transducer and activator of transcription 3; stem cell factor; suppressor of cytokine signaling 3
Authors: Daniel Traum; Patricia Timothee; Jonathan Silver; Stefan Rose-John; Matthias Ernst; David F LaRosa Journal: J Leukoc Biol Date: 2011-12-02 Impact factor: 4.962
Authors: S J Rodig; M A Meraz; J M White; P A Lampe; J K Riley; C D Arthur; K L King; K C Sheehan; L Yin; D Pennica; E M Johnson; R D Schreiber Journal: Cell Date: 1998-05-01 Impact factor: 41.582
Authors: Christian Hundhausen; Dominika Misztela; Theo A Berkhout; Neil Broadway; Paul Saftig; Karina Reiss; Dieter Hartmann; Falk Fahrenholz; Rolf Postina; Vance Matthews; Karl-Josef Kallen; Stefan Rose-John; Andreas Ludwig Journal: Blood Date: 2003-04-24 Impact factor: 22.113
Authors: Thomas R Hundley; Alasdair M Gilfillan; Christine Tkaczyk; Marcus V Andrade; Dean D Metcalfe; Michael A Beaven Journal: Blood Date: 2004-06-24 Impact factor: 22.113
Authors: Jorge Esparza-Gordillo; Heidi Schaarschmidt; Liming Liang; William Cookson; Anja Bauerfeind; Min-Ae Lee-Kirsch; Katja Nemat; John Henderson; Lavinia Paternoster; John I Harper; Elisabeth Mangold; Markus M Nothen; Franz Rüschendorf; Tamara Kerscher; Ingo Marenholz; Anja Matanovic; Susanne Lau; Thomas Keil; Carl-Peter Bauer; Michael Kurek; Andrzej Ciechanowicz; Milan Macek; Andre Franke; Michael Kabesch; Norbert Hubner; Gonçalo Abecasis; Stephan Weidinger; Miriam Moffatt; Young-Ae Lee Journal: J Allergy Clin Immunol Date: 2013-04-09 Impact factor: 10.793
Authors: Joakim S Dahlin; Maria Ekoff; Jennine Grootens; Liza Löf; Rose-Marie Amini; Hans Hagberg; Johanna S Ungerstedt; Ulla Olsson-Strömberg; Gunnar Nilsson Journal: Blood Date: 2017-08-08 Impact factor: 22.113
Authors: Herbert Renz-Polster; Marie-Eve Tremblay; Dorothee Bienzle; Joachim E Fischer Journal: Front Cell Neurosci Date: 2022-05-09 Impact factor: 6.147